For laboratory research use only · Not for human or veterinary use · 18+
Metabolic research

Buy Retatrutide Cagrilintide Blend in Australia

Lyophilised powder, 15mg vial · Available to order, dispatched from Australia
$239.99

Buy the Retatrutide Cagrilintide blend in Australia from Macropus Peptides as a single 15mg research vial, priced and ready to order. The vial pairs two metabolic peptides that act on separate hormone systems: a triple agonist of the GLP-1, GIP and glucagon receptors, and a long-acting amylin analogue that works through amylin and calcitonin receptors. Both are co-lyophilised into one powder, so a single reconstitution gives a working stock that holds them at a fixed ratio, with the amount of each peptide printed on the label and recorded on the certificate of analysis for the lot. It suits laboratories studying how incretin and amylin signalling combine without preparing two vials. Order online, add bacteriostatic water, and your parcel ships from inside Australia to any address in the country. The Retatrutide Cagrilintide blend is sold for in-vitro laboratory research only, to buyers aged 18 and over, and is not for human or veterinary use.

1
Frequently bought together
For in-vitro laboratory research only. Not for human or veterinary use. Purchasers must be 18 or over.
CompoundRetatrutide + Cagrilintide blend
Amount15 mg
FormLyophilised powder
CategoryMetabolic research
Storage-20 °C, protect from light
TestingHPLC purity and mass spectrometry identity, every batch
Certificate of analysisAvailable for every lot, matched to the lot number on the label
Peptide calculator

Retatrutide + Cagrilintide blend 15mg vial

Enter the diluent volume added to this vial to see the solution concentration. Laboratory calculation only, not dosing guidance.

Vial content
15 mg
mg per mL7.50
mcg per mL7,500

Buy Retatrutide Cagrilintide Blend Australia: 15mg Vial

Macropus Peptides offers this pairing as a single 15mg vial with a listed price, a triple incretin agonist and an amylin analogue freeze-dried together. It sits in our metabolic range beside the two single peptides it is made from, and exists for studies that need both pathways active in one preparation from one lot.

What is the Retatrutide Cagrilintide blend

The vial holds two synthetic peptides with different targets. The first, Retatrutide, is a lipidated peptide that activates the GLP-1, GIP and glucagon receptors from one molecule. The second, Cagrilintide, is a modified form of amylin, the hormone co-secreted with insulin by pancreatic beta cells, engineered to resist fibril formation and to bind albumin. Both carry fatty acid chains that give them half-lives measured in days, part of why they suit a shared vial. The two chains are not chemically linked; they simply share one dried cake, and the label and certificate state how many milligrams of each your lot contains.

How Retatrutide and Cagrilintide work together in research

Incretin and glucagon receptors belong to the class B family of G protein-coupled receptors and are found on pancreatic islet cells, liver cells and neurons in the hypothalamus. Amylin receptors are assembled differently, from the calcitonin receptor plus one of three accessory proteins called RAMPs, and their best-described sites of action lie in the brainstem, especially the area postrema. Because the two peptides reach different receptor families in different brain regions, combining them lets researchers ask whether the signals add together or interact. That is the core question of amylin plus incretin research, and a co-formulated vial means both compounds are present in every aliquot at the same ratio.

Why buy Retatrutide and Cagrilintide combined in one vial

Preparing two separate peptides for every experiment doubles the reconstitution work and adds a mixing step where ratio errors creep in. A pre-blended vial removes that step and ties both compounds to a single lot number, so every sample in a series draws on identical material. It also keeps two lipidated peptides, which behave similarly in solution, handled under one set of conditions.

Retatrutide Cagrilintide research: what the studies show

No published study has tested this exact pair together, so the research base comes from each component and from the wider amylin plus incretin approach. The triple agonist was taken from discovery to first human data in a 2022 Cell Metabolism report, and a 2021 medicinal chemistry paper detailed how the amylin analogue was designed and acylated. For the combination principle, a 2010 study in the American Journal of Physiology examined a GLP-1 receptor agonist given with a calcitonin receptor agonist in nonhuman primates. In people, The Lancet published a phase 1b trial in 2021 and a phase 2 trial in type 2 diabetes in 2023 that paired the amylin analogue with a different GLP-1 receptor agonist, measuring pharmacokinetics, tolerability and glycaemic markers. Each paper is labelled by what it studied in our Retatrutide Cagrilintide research studies library.

Retatrutide Cagrilintide blend vial specifications

SpecificationDetail
CompoundRetatrutide + Cagrilintide blend
Amount15 mg
FormLyophilised powder
CategoryMetabolic research
Storage-20 °C, protect from light

A single lyophilised cake carries both peptides inside a crimp-sealed glass vial. Its label names each compound with its own fill weight, alongside the batch code and freezer temperature, and that batch code is how we locate the matching certificate. Until use, the co-lyophilised vial lives frozen at -20 °C with light kept off it.

Retatrutide Cagrilintide blend price in Australia

StrengthPricePrice per mg
Retatrutide + Cagrilintide blend 15mg$239.99$16.00 per mg

The 15mg vial has one listed price and ships from stock. The cheapest way to get both peptides as singles, one 10mg vial of each, costs noticeably more in total than a blended vial, although that pair holds more peptide overall.

Retatrutide Cagrilintide 15mg: where to buy in Australia

Fifteen milligrams is the only size of this combination we make. Whatever volume you draw from the reconstituted vial, both components come out at the ratio printed on the label. Combined-peptide strengths for common volumes:

  • 1.5 mL: 10 mg per mL
  • 3 mL: 5 mg per mL
  • 5 mL: 3 mg per mL

Retatrutide Cagrilintide blend or single vials: which to buy

Pick the blend when every arm of a study runs both peptides at the labelled ratio, because one vial and one lot cover the whole design. Pick the single Retatrutide and Cagrilintide vials when a control arm must carry just one of the two compounds, or when the ratio between them is itself the variable under test. Many groups buy both: the blend for combination arms and the singles for controls.

Best place to buy Retatrutide Cagrilintide blend Australia

  • Two metabolic peptides co-lyophilised in one priced 15mg vial
  • Content of each component on label and certificate
  • Both single peptides stocked for control arms
  • Shipped domestically from Australia, clear of customs holds
  • Diluents and consumables available in the same order

How to buy Retatrutide Cagrilintide blend online

  • Place the 15mg blend in your cart
  • Add single vials if your design includes controls
  • Include bacteriostatic water for reconstitution
  • Check out as an adult ordering for lab work
  • File the batch code for a later certificate request

Retatrutide Cagrilintide calculator: mixing the 15mg vial

Enter any diluent volume into the listing's calculator to see the combined concentration, then enter the label split to see each peptide's share. Run bacteriostatic water 10mL down the inner wall and roll the vial gently, since shaking can make lipidated peptides foam. Syringes and swabs are in lab supplies.

Is the Retatrutide Cagrilintide blend available in Australia

Yes, as bench material only. Neither component appears on the ARTG, and no product combining them has TGA approval, so neither people nor animals may receive it. We sell the vial for in-vitro research, and since the Poisons Standard is amended every so often, confirm your organisation's scheduling position before ordering.

Retatrutide Cagrilintide blend for sale Australia wide

Parcels travel from within Australia to every capital and regional centre, the vial upright and its cap shielded. Laboratories comparing incretin chemistries often add Tirzepatide as the dual agonist reference, and the rest of our metabolic research range is listed compound by compound.

References

  1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022.
  2. Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry. 2021.
  3. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2010.
  4. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 2023.

Scientific content compiled from the peer-reviewed literature above by the Macropus Peptides technical team. Information is provided for research reference only.

Questions about Retatrutide + Cagrilintide blend 15mg

Chat on WhatsApp
Retatrutide + Cagrilintide blend 15mg$239.99